BRPI0409698A - derivados de triaza- e tetraaza-antracenodiona, preparação dos mesmos e uso dos mesmos como produtos farmacêuticos - Google Patents
derivados de triaza- e tetraaza-antracenodiona, preparação dos mesmos e uso dos mesmos como produtos farmacêuticosInfo
- Publication number
- BRPI0409698A BRPI0409698A BRPI0409698-3A BRPI0409698A BRPI0409698A BR PI0409698 A BRPI0409698 A BR PI0409698A BR PI0409698 A BRPI0409698 A BR PI0409698A BR PI0409698 A BRPI0409698 A BR PI0409698A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- phenyl
- triaza
- tetraaza
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
"DERIVADOS DE TRIAZA- E TETRAAZAANTRACENODIONA, PREPARAçãO DOS MESMOS E USO DOS MESMOS COMO PRODUTOS FARMACêUTICOS". A presente invenção refere-se a derivados de triaza- e tetraazaantracenodiona de fórmula (I) em que A, B e R¬ 1¬ a R¬ 5¬ têm os significados indicados nas reivindicações. Os compostos de fórmula I são compostos valiosos farmacologicamente ativos. Eles são úteis no tratamento de vários estados de doença inclusive distúrbios cardiovasculares tais como aterosclerose, trombose, doença da artéria coronariana, hipertensão e insuficiência cardíaca. Eles controlam a expressão da enzima (NO) sintase endotelial e podem ser aplicados em condições em que é desejado uma maior expressão da dita enzima ou um nível mais alto de NO ou a normalização de um nível diminuído de NO. A invenção também se refere a processos para a preparação de compostos de fórmula I, seu uso, em particular como ingredientes ativos em produtos farmacêuticos e em preparações farmacêuticas que compreendem os mesmos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20030009286 EP1471066A1 (en) | 2003-04-24 | 2003-04-24 | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals |
PCT/EP2004/003851 WO2004094425A1 (en) | 2003-04-24 | 2004-04-13 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0409698A true BRPI0409698A (pt) | 2006-04-18 |
Family
ID=32946872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0409698-3A BRPI0409698A (pt) | 2003-04-24 | 2004-04-13 | derivados de triaza- e tetraaza-antracenodiona, preparação dos mesmos e uso dos mesmos como produtos farmacêuticos |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1471066A1 (pt) |
JP (1) | JP4603530B2 (pt) |
AT (1) | ATE501144T1 (pt) |
AU (1) | AU2004232456B2 (pt) |
BR (1) | BRPI0409698A (pt) |
CA (1) | CA2523196C (pt) |
DE (1) | DE602004031734D1 (pt) |
DK (1) | DK1641795T3 (pt) |
ES (1) | ES2362658T3 (pt) |
IL (1) | IL171500A (pt) |
MX (1) | MXPA05011267A (pt) |
PT (1) | PT1641795E (pt) |
WO (1) | WO2004094425A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238702B2 (en) | 2005-02-10 | 2007-07-03 | Bristol-Myers Squibb Company | Dihydroquinazolinones as 5HT modulators |
EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
EP1905764A1 (en) | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
EP1923062A1 (en) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |
EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
GB2575490A (en) * | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
WO2021048364A1 (en) * | 2019-09-11 | 2021-03-18 | Solvay Sa | Process for manufacturing a substituted cyclohexanecarbonitrile |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294517B1 (en) * | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
-
2003
- 2003-04-24 EP EP20030009286 patent/EP1471066A1/en not_active Withdrawn
-
2004
- 2004-04-13 BR BRPI0409698-3A patent/BRPI0409698A/pt not_active IP Right Cessation
- 2004-04-13 AU AU2004232456A patent/AU2004232456B2/en not_active Ceased
- 2004-04-13 PT PT04726960T patent/PT1641795E/pt unknown
- 2004-04-13 ES ES04726960T patent/ES2362658T3/es not_active Expired - Lifetime
- 2004-04-13 MX MXPA05011267A patent/MXPA05011267A/es active IP Right Grant
- 2004-04-13 CA CA2523196A patent/CA2523196C/en not_active Expired - Fee Related
- 2004-04-13 AT AT04726960T patent/ATE501144T1/de active
- 2004-04-13 WO PCT/EP2004/003851 patent/WO2004094425A1/en active Application Filing
- 2004-04-13 DE DE602004031734T patent/DE602004031734D1/de not_active Expired - Lifetime
- 2004-04-13 DK DK04726960.0T patent/DK1641795T3/da active
- 2004-04-13 JP JP2006505091A patent/JP4603530B2/ja not_active Expired - Fee Related
- 2004-04-13 EP EP04726960A patent/EP1641795B1/en not_active Expired - Lifetime
-
2005
- 2005-10-20 IL IL171500A patent/IL171500A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE501144T1 (de) | 2011-03-15 |
JP4603530B2 (ja) | 2010-12-22 |
IL171500A (en) | 2010-06-30 |
PT1641795E (pt) | 2011-05-18 |
CA2523196C (en) | 2012-05-29 |
EP1641795B1 (en) | 2011-03-09 |
MXPA05011267A (es) | 2006-05-25 |
EP1641795A1 (en) | 2006-04-05 |
JP2006524197A (ja) | 2006-10-26 |
WO2004094425A1 (en) | 2004-11-04 |
DK1641795T3 (da) | 2011-06-27 |
ES2362658T3 (es) | 2011-07-11 |
EP1471066A1 (en) | 2004-10-27 |
AU2004232456A1 (en) | 2004-11-04 |
CA2523196A1 (en) | 2004-11-04 |
DE602004031734D1 (de) | 2011-04-21 |
AU2004232456B2 (en) | 2010-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0409698A (pt) | derivados de triaza- e tetraaza-antracenodiona, preparação dos mesmos e uso dos mesmos como produtos farmacêuticos | |
AU2009278442B2 (en) | Imidazopyridin-2-one Derivatives | |
AU2004309279B2 (en) | Thiazole derivative | |
KR101949624B1 (ko) | Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체 | |
CA2787291C (en) | 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds | |
DK1921077T3 (en) | Means for treating and / or preventing sleep disorders | |
US11912699B2 (en) | Tau-protein targeting compounds and associated | |
RU2008125068A (ru) | Спироциклические соединения | |
JP6080226B2 (ja) | 他の活性物質と組み合わせたロイコトリエン産生阻害用ベンゾジオキサン | |
EA035049B1 (ru) | СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ | |
RU2012131129A (ru) | Соединения замещенного n-(1н-индазол-4-ил)имидазол[1,2-а]-3-карбоксамида как ингибиторы cfms | |
AU2012325971B2 (en) | Compounds and methods for enhancing innate immune responses | |
KR20190075931A (ko) | 스피로 고리 화합물 | |
JP2009516743A5 (pt) | ||
US11173211B2 (en) | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | |
CZ20032316A3 (cs) | Prostředky obsahující substituované deriváty azaindoloxoacetylpiperazinu a jejich antivirová aktivita | |
HRP20231734T1 (hr) | Triciklički akr1c3 ovisni kars inhibitori | |
AU2013218354A1 (en) | Furo [3, 2 - b] - and thieno [3, 2 - b] pyridine derivatives as TBK1 and IKK inhibitors | |
WO2004055011A1 (en) | Heterocyclic compounds as ccr5 antagonists | |
TW202214598A (zh) | 快速加速纖維肉瘤蛋白質降解之化合物及相關使用方法 | |
US20070232644A1 (en) | Inhibitors of the Hiv Integrase Enzyme | |
RU2014146993A (ru) | Производное хиназолиндиона | |
JP2023545545A (ja) | 複素環スピロ化合物及び使用方法 | |
EA037598B1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диазаспиро[4,5]декана | |
WO2022172037A1 (en) | Compounds and their use as pde4 activators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |